<DOC>
	<DOC>NCT02643784</DOC>
	<brief_summary>This is an exploratory, randomized, open-label, 2-arm, parallel-group study exploring the efficacy of rosuvastatin (20mg/day) in patients with acute ischemic stroke.</brief_summary>
	<brief_title>Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description>This is a 90-day, explanatory; randomized; open-label, 2-arm; parallel group with blinded outcome evaluation study exploring the efficacy and study of early rosuvastatin 20 mg/d treatment in acute ischemic patients with stroke onset in 24 hours.</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1. 45 to 75 years old patients; 2. Stroke involving the vascular territory of the middle cerebral artery (MCA) as judged by clinical and MRI evidences; 3. Time from symptom onset to take the study assigned medication is within 24 hours; 4. Statin naïve or discontinued at least 3 month before stroke onset; 5. First ever stroke or mild sequelae (with modified Rankin Score 01) before the index event; 6. Moderate neurological deficit with baseline NIHSS scoring from 420; 7. MRI scans （T1W1、T2W2、T2Flair、DWI、SWI）accomplished from 12 to 48 hours after the onset; 8. Consent form signed. Any of the following is regarded as a criterion for exclusion from the study: 1. Stroke involving the vascular territory of the vertebrobasilar artery as judged by clinical and MRI evidences; 2. Hemorrhagic transformation or intracranial hemorrhage on baseline MRI. MRI performed between 1248 hours after the onset, if MRI provides evidences which met with the exclusion criteria, the patients will be excluded from the study; 3. Any circumstances under which MRI scans can't be performed; 4. Evidences suggesting cardiogenic stroke such as atrial fibrillation, acute coronary syndrome, patent foramen ovale , etc; 5. Comatose with NIHSS 1a&gt;1; 6. Medical or psychiatric conditions such as severe hepatic or renal dysfunction, heart failure, malignancy, major depression, dementia, alcohol or drug abuse; 7. Suitable for rtPlasminogen Activator thrombolysis treatment; 8. Receiving medication with possible neuroprotective functions after stroke onset; 9. Currently take steroids therapy; 10. Diagnosed with malignancy within 5 years; 11. Patients with myopathy or serum creatine kinase &gt; 3 times the upper limit of normal not caused by myocardial injury; 12. Severe renal function damage (eGFR&lt;30); 13. Concurrent use ciclosporin; 14. A history of hypersensitivity of statins and other severe complication; 15. Childbearing women ; 16. Patients who are or may be pregnant; 17. Other conditions under which patients not pertinent to attend the study as judged by the investigators.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>acute ischemic stroke</keyword>
</DOC>